Evaluation of PKU UP

Sponsor

Vitaflo International, Ltd (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT05995717

Collaborator

Birmingham Women's and Children's NHS Foundation Trust (Other)

Enrollment

Locations

Arm

Anticipated Duration (Months)

3.8

Patients Per Site

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

PKU UP is a prospective, single-arm, open-label, 26-week acceptability study to evaluate PKU UP for the dietary management of participants with phenylketonuria (PKU). Up to 15 participants aged 1 - 10 years old will be recruited and it is anticipated the study will open in at least three sites in the United Kingdom (UK) to recruit the target number of participants in the required timeframe.

Condition or Disease	Intervention/Treatment	Phase
PKU	Dietary Supplement: PKU UP	N/A

Detailed Description

PKU is a rare inborn error of metabolism with a prevalence of 1 in 10,000 in the UK population. The mainstay of treatment for most individuals is dietary therapy with a strict protein-restricted diet. We propose to recruit children with a diagnosis of PKU aged 1-10 years.

The study product, PKU UP, is a food for special medical purposes (FSMP), as defined by the Delegated Act EU 2016/128, used for the dietary management of Phenylketonuria (PKU).

The study will be investigating the acceptability of PKU UP, as defined by the Advisory

Committee on Borderline Substances (ACBS). This includes the following:

participant adherence to recommended intakes
gastrointestinal symptoms
evaluations of palatability.

Each participant will be on the study for 26 weeks. This includes evaluation part 1 and evaluation part 2:

Part 1 consists of a 12 week period where participants introduce the study product into their diet. Gastrointestinal tolerance, metabolic control, compliance, product acceptability and dietary quality will be evaluated.
Part 2 consists of a 14 week period where participants continue to take the study product for a longer assessment of growth and nutritional status.

Data collection will be performed using paper and/or electronic Case Report Forms completed by the investigators at the baseline, evaluation periods and end of study visits. There will also be three questionnaires completed by the parents/guardians over the course of the study, in relation to protein substitute intake, gastrointestinal tolerance, and product acceptability.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

15 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

An Acceptability Study to Evaluate the Compliance, Gastrointestinal Tolerance, Palatability and Metabolic Control of Children With Phenylketonuria (PKU) When Using PKU UP (a Food for Special Medical Purposes) as Part of Dietary Management.

Anticipated Study Start Date :

Oct 16, 2023

Anticipated Primary Completion Date :

Apr 16, 2025

Anticipated Study Completion Date :

Jun 16, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: PKU UP All participants will be assessed by their dietitian and prescribed an appropriate amount of the study product, PKU UP, to manage their phenylketonuria.	Dietary Supplement: PKU UP PKU UP is a food for special medical purposes (FSMP). This product is for use in the dietary management of Phenylketonuria (PKU) in children aged from one (1) to ten (10) years. PKU UP is a neutral-flavoured, ready-to-drink, low-phenylalanine protein substitute containing a blend of glycomacropeptide (GMP) isolate, essential and non-essential amino acids, fat, carbohydrate, vitamins, minerals and docosahexaenoic acid (DHA).

Arm

Intervention/Treatment

Experimental: PKU UP

All participants will be assessed by their dietitian and prescribed an appropriate amount of the study product, PKU UP, to manage their phenylketonuria.

Dietary Supplement: PKU UP

PKU UP is a food for special medical purposes (FSMP). This product is for use in the dietary management of Phenylketonuria (PKU) in children aged from one (1) to ten (10) years. PKU UP is a neutral-flavoured, ready-to-drink, low-phenylalanine protein substitute containing a blend of glycomacropeptide (GMP) isolate, essential and non-essential amino acids, fat, carbohydrate, vitamins, minerals and docosahexaenoic acid (DHA).

Outcome Measures

Primary Outcome Measures

Change in phe level between baseline and visit 3 [26 weeks]
Change in phe level as measured by dried blood spot testing
Change in tyrosine level between baseline and visit 3 [26 weeks]
Change in tyrosine level as measured by dried blood spot testing
Change in PI impression of metabolic control [Week 0, week 6, week 12, week 26]
Assessment of the participant's metabolic control in the opinion of the investigator
Change in the growth of participants as measured by Height (length in under 2 years of age), Head circumference in under 2 years of age and Weight. [Week 0, week 12, week 26]
Assessed via anthropometry measurements. Participants will be weighed and measured for growth monitoring.
Change in GI tolerance (participant) [Week 0, week 6, week 12, week 26]
Gastrointestinal tolerance assessed using the PedsQL Gastrointestinal Symptoms Scale completed by the participants
Change in PI impression of GI tolerance [Week 0, week 6, week 12, week 26]
Assessment of the participant's GI tolerance in the opinion of the investigator
Change in compliance with study product consumption [Week 0, week 6, week 12, week 26]
Assessed via participant diary regarding study product intake
Change in PI impression of study product intake [Week 0, week 6, week 12, week 26]
Assessment of the participant's compliance in the opinion of the investigator
Change in product acceptability [Week 0, week 12, week 26]
Assessed via a product acceptability questionnaire completed by the participant/parent
Change in dietary intake [Week 0, week 12, week 26]
Assessed via 24-hour recall and low protein food frequency questionnaire
Change in nutritional biochemistry [Week 0, week 26]
Assessed via venous blood sample of approximately 7ml

Eligibility Criteria

Criteria

Ages Eligible for Study:

1 Year to 10 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Diagnosis of PKU requiring a low-protein diet and protein substitute.
Participants who are adherent with their blood phenylalanine (Phe) testing, in the opinion of the investigator.
Participants aged 1-10 years.
Participants who are anticipated to be able to take at least half of their daily protein equivalent requirement from PKU UP.
Willingly given, written, informed consent from the parent(s)/guardian(s).
Willingly given, written assent by the participant (if appropriate).

Exclusion Criteria:

Inability to comply with the study protocol, in the opinion of the investigator.
Any co-morbidity, which, in the opinion of the investigator, would preclude participation in the study.
Diagnosis of persistent hyperphenylalaninemia, or mild PKU not requiring a low protein diet and protein substitute.
Allergy or intolerance to milk.
Participants who are currently participating in, plan to participate in or have participated in an interventional investigational drug, food or medical device study within 30 days prior to the screening visit.
Use of additional micronutrient supplements during the evaluation period, unless clinically indicated and prescribed by the Investigator (must be recorded in both the medical records and case report form).

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	Royal Belfast Hospital for Sick Children	Belfast	United Kingdom	BT12 6BE
2	Birmingham Children's Hospital	Birmingham	United Kingdom	B4 6NH
3	University Hospitals Bristol and Weston NHS Foundation Trust	Bristol	United Kingdom	BS2 8BJ
4	Great Ormond Street Hospital for Children NHS Foundation Trust	London	United Kingdom	WC1N 3JH